{"id":"nurown-msc-ntf-cells","safety":{"commonSideEffects":[{"rate":null,"effect":"Back pain"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Procedural pain at injection site"},{"rate":null,"effect":"Transient lower limb weakness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"NurOwn (MSC-NTF cells) consists of autologous bone marrow-derived mesenchymal stem cells that have been differentiated ex vivo to produce and secrete neurotrophic factors, including nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and glial-derived neurotrophic factor (GDNF). These factors are intended to slow motor neuron degeneration and preserve motor function in ALS patients. The cells are injected intrathecally into the cerebrospinal fluid to deliver these neuroprotective factors directly to affected motor neurons.","oneSentence":"NurOwn delivers mesenchymal stem cells engineered to secrete neurotrophic factors that support motor neuron survival and function in amyotrophic lateral sclerosis (ALS).","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:23:38.778Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Amyotrophic lateral sclerosis (ALS)"}]},"trialDetails":[{"nctId":"NCT04681118","phase":"","title":"Expanded Access Protocol: Repeated Administration of Nurown® (Autologous MSC-NTF Cells) for the Treatment of ALS","status":"NO_LONGER_AVAILABLE","sponsor":"Brainstorm-Cell Therapeutics","startDate":"","conditions":"Amyotrophic Lateral Sclerosis","enrollment":""},{"nctId":"NCT03280056","phase":"PHASE3","title":"Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients","status":"COMPLETED","sponsor":"Brainstorm-Cell Therapeutics","startDate":"2017-08-28","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":196},{"nctId":"NCT03799718","phase":"PHASE2","title":"Safety and Efficacy of Repeated Administration of NurOwn (MSC-NTF Cells) in Participants With Progressive MS","status":"COMPLETED","sponsor":"Brainstorm-Cell Therapeutics","startDate":"2019-03-13","conditions":"Multiple Sclerosis, Chronic Progressive","enrollment":23}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["NurOwn"],"phase":"phase_3","status":"active","brandName":"NurOwn® (MSC-NTF cells)","genericName":"NurOwn® (MSC-NTF cells)","companyName":"Brainstorm-Cell Therapeutics","companyId":"brainstorm-cell-therapeutics","modality":"Biologic","firstApprovalDate":"","aiSummary":"NurOwn delivers mesenchymal stem cells engineered to secrete neurotrophic factors that support motor neuron survival and function in amyotrophic lateral sclerosis (ALS). Used for Amyotrophic lateral sclerosis (ALS).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}